...
search icon
cue-img

Cue Biopharma Share Price

CUE
NAQ
$0.3201
+$0
(0%)
1D
Industry: Biotechnology Sector: Health Care

Cue Biopharma Analyst Forecast

Cue Biopharma Share Price Chart

Cue Biopharma Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$28.84M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
379.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.50
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.23 L
$1.54 H
$0.3201

About Cue Biopharma, Common Stock

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Cue Biopharma Stock Returns

Time FrameCUESectorS&P500
1-Week Return-4.39%0.06%-2.06%
1-Month Return-12.8%-2.06%-2.06%
3-Month Return-55.29%6.1%1.11%
6-Month Return-59.12%18.64%7.13%
1-Year Return-76.29%5.25%11.74%
3-Year Return-91.4%17.35%65.43%
5-Year Return-98.01%33.7%73.53%
10-Year Return-97.25%143.77%266.66%

Cue Biopharma Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue3.15M14.94M1.25M5.49M9.29M[{"date":"2020-12-31","value":21.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.33,"profit":true},{"date":"2023-12-31","value":36.74,"profit":true},{"date":"2024-12-31","value":62.16,"profit":true}]
Cost of Revenue33.55M(1.78M)1.81M38.10M2.35M[{"date":"2020-12-31","value":88.05,"profit":true},{"date":"2021-12-31","value":-4.67,"profit":false},{"date":"2022-12-31","value":4.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":6.17,"profit":true}]
Gross Profit(30.39M)14.94M1.25M(32.61M)9.29M[{"date":"2020-12-31","value":-203.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.33,"profit":true},{"date":"2023-12-31","value":-218.23,"profit":false},{"date":"2024-12-31","value":62.16,"profit":true}]
Gross Margin(963.48%)100.00%100.00%(593.93%)100.00%[{"date":"2020-12-31","value":-963.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-593.93,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses14.65M58.65M54.47M19.54M50.79M[{"date":"2020-12-31","value":24.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.87,"profit":true},{"date":"2023-12-31","value":33.32,"profit":true},{"date":"2024-12-31","value":86.59,"profit":true}]
Operating Income(45.04M)(43.71M)(53.23M)(52.15M)(41.50M)[{"date":"2020-12-31","value":-4504258500,"profit":false},{"date":"2021-12-31","value":-4371207300,"profit":false},{"date":"2022-12-31","value":-5322500000,"profit":false},{"date":"2023-12-31","value":-5214900000,"profit":false},{"date":"2024-12-31","value":-4150000000,"profit":false}]
Total Non-Operating Income/Expense927.83K91.80K429.43K2.83M1.65M[{"date":"2020-12-31","value":32.76,"profit":true},{"date":"2021-12-31","value":3.24,"profit":true},{"date":"2022-12-31","value":15.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":58.33,"profit":true}]
Pre-Tax Income(44.58M)(43.67M)(53.01M)(50.73M)(40.67M)[{"date":"2020-12-31","value":-4457867100,"profit":false},{"date":"2021-12-31","value":-4366617500,"profit":false},{"date":"2022-12-31","value":-5301000000,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false},{"date":"2024-12-31","value":-4067400000,"profit":false}]
Income Taxes206.25K495.00K(214.43K)3.27M(40.67M)[{"date":"2020-12-31","value":6.31,"profit":true},{"date":"2021-12-31","value":15.15,"profit":true},{"date":"2022-12-31","value":-6.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1244.57,"profit":false}]
Income After Taxes(44.78M)(44.16M)(52.80M)(54.00M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(44.78M)(44.16M)(53.01M)(50.73M)(40.67M)[{"date":"2020-12-31","value":-4478492100,"profit":false},{"date":"2021-12-31","value":-4416117500,"profit":false},{"date":"2022-12-31","value":-5301038200,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false},{"date":"2024-12-31","value":-4067400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(44.78M)(44.16M)(53.01M)(50.73M)(40.67M)[{"date":"2020-12-31","value":-4478492100,"profit":false},{"date":"2021-12-31","value":-4416117500,"profit":false},{"date":"2022-12-31","value":-5301000000,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false},{"date":"2024-12-31","value":-4067400000,"profit":false}]
EPS (Diluted)(1.56)(1.40)(1.50)(1.11)(0.75)[{"date":"2020-12-31","value":-156,"profit":false},{"date":"2021-12-31","value":-140,"profit":false},{"date":"2022-12-31","value":-150,"profit":false},{"date":"2023-12-31","value":-111,"profit":false},{"date":"2024-12-31","value":-74.89,"profit":false}]

Cue Biopharma Ratios

Cue Biopharma Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CUE
Cash Ratio 1.20
Current Ratio 1.66

Cue Biopharma Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CUE
ROA (LTM) -62.31%
ROE (LTM) -195.19%

Cue Biopharma Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CUE
Debt Ratio Lower is generally better. Negative is bad. 0.58
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.42

Cue Biopharma Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CUE
Trailing PE NM
Forward PE NM
P/S (TTM) 4.06
P/B 2.13
Price/FCF NM
EV/R 2.21
EV/Ebitda NM

FAQs

What is Cue Biopharma share price today?

Cue Biopharma (CUE) share price today is $0.3201

Can Indians buy Cue Biopharma shares?

Yes, Indians can buy shares of Cue Biopharma (CUE) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CUE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cue Biopharma be purchased?

Yes, you can purchase fractional shares of Cue Biopharma (CUE) via the Vested app. You can start investing in Cue Biopharma (CUE) with a minimum investment of $1.

How to invest in Cue Biopharma shares from India?

You can invest in shares of Cue Biopharma (CUE) via Vested in three simple steps:

  • Click on Sign Up or Invest in CUE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cue Biopharma shares
What is Cue Biopharma 52-week high and low stock price?

The 52-week high price of Cue Biopharma (CUE) is $1.54. The 52-week low price of Cue Biopharma (CUE) is $0.23.

What is Cue Biopharma price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cue Biopharma (CUE) is

What is Cue Biopharma price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cue Biopharma (CUE) is 2.13

What is Cue Biopharma dividend yield?

The dividend yield of Cue Biopharma (CUE) is 0.00%

What is the Market Cap of Cue Biopharma?

The market capitalization of Cue Biopharma (CUE) is $28.84M

What is Cue Biopharma's stock symbol?

The stock symbol (or ticker) of Cue Biopharma is CUE

How Can Investors Use Cue Biopharma Share Price Data for Long-Term Investment Decisions?

Consider the share price of Cue Biopharma as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cue Biopharma has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Cue Biopharma shares for Indian investors?

When investing in Cue Biopharma shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cue Biopharma stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Cue Biopharma share price with other stocks in the same sector?

Rather than merely checking the share price of Cue Biopharma and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cue Biopharma stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top